Company intelligence / Profile preview

Motif Bio plc

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Motif Bio was a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. Its lead candidate, iclaprim—a DHFR inhibitor—completed two Phase 3 trials for ABSSSI but received a Complete Response Letter from the FDA in 2019 due to concerns about liver toxicity risk. The failure to gain approval led to the company's demise; it was dissolved in December 2022[1][6].

Therapeutic areas: Infectious Diseases
Modalities: small molecules (notably diaminopyrimidine antibiotics)
Industry: Biotech

Drug pipeline

2 assets

Iclaprim

1 more asset in the full pipeline.

Partnerships

No major pharmaceutical partnerships reported; discussions with academic institutes for licensing were underway as of last updates[5].

Beyond the preview

Go deeper on Motif Bio plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Motif Bio plc.